EA
ITCI

Emerald Advisers’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Emerald Advisers’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-438,066
Closed -$36.6M – 273
2024
Q4 		$36.6M Sell
438,066
-3,230
-0.7% -$265K 1.42% 15
2024
Q3 		$32.3M Buy
441,296
+48,705
+12% +$3.66M 1.25% 22
2024
Q2 		$26.9M Sell
392,591
-9,020
-2% -$626K 1.13% 29
2024
Q1 		$27.8M Buy
401,611
+57,791
+17% +$3.97M 1.12% 28
2023
Q4 		$24.6M Sell
343,820
-37,920
-10% -$2.18M 1.05% 31
2023
Q3 		$19.9M Buy
381,740
+46,574
+14% +$2.71M 0.96% 40
2023
Q2 		$21.2M Buy
+335,166
New +$20.9M 0.93% 45

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Emerald Advisers's ITCI Position: Q1 2025 in Review

Emerald Advisers sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 438,066 shares — an estimated $36.6M sold.

Emerald Advisers first reported a position in ITCI in Q2 2023 and held it in 7 quarters. The position peaked at $36.6M in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Emerald Advisers reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Emerald Advisers sold 438,066 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $36.6M.
  • Emerald Advisers first reported a position in Intra-Cellular Therapies Inc. in Q2 2023 and held it in 7 quarters.
  • Emerald Advisers's Intra-Cellular Therapies Inc. position peaked at $36.6M in Q4 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Emerald Advisers's 13F filing for Q1 2025, filed 1 May 2025.